Trials / Completed
CompletedNCT04550325
Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19
A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Kamada, Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Kamada Anti-SARS-CoV-2 | Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods |
Timeline
- Start date
- 2020-08-05
- Primary completion
- 2020-11-26
- Completion
- 2020-11-26
- First posted
- 2020-09-16
- Last updated
- 2021-01-05
Locations
4 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT04550325. Inclusion in this directory is not an endorsement.